A5032252442- Cancer Risks and Factors
- Breast Cancer Treatment Studies
- Galectins and Cancer Biology
- Glycosylation and Glycoproteins Research
- Reproductive Biology and Fertility
- HER2/EGFR in Cancer Research
- Toxin Mechanisms and Immunotoxins
- Multiple and Secondary Primary Cancers
- BRCA gene mutations in cancer
- Gene expression and cancer classification
- Bioinformatics and Genomic Networks
- Childhood Cancer Survivors' Quality of Life
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- AI in cancer detection
- Global Cancer Incidence and Screening
- Renal and related cancers
- Lung Cancer Treatments and Mutations
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Chronic Lymphocytic Leukemia Research
- Estrogen and related hormone effects
- Lung Cancer Research Studies
- Ovarian cancer diagnosis and treatment
Hospital Zambrano Hellion
2019-2025
Tecnológico de Monterrey
2019-2025
Institut Jules Bordet
2012-2024
Dana-Farber Cancer Institute
2024
KK Women's and Children's Hospital
2024
Kenyatta University
2024
American University of Beirut
2017-2021
Innate Pharma (France)
2018-2021
International Breast Cancer Study Group
2021
Université Libre de Bruxelles
2010-2020
Breast cancer in young women is associated with poor prognosis. We aimed to define the role of gene expression signatures predicting prognosis and understand biological differences according age.Patients were assigned molecular subtypes [estrogen receptor (ER)(+)/HER2(-); HER2(+), ER(-)/HER2(-))] using a three-gene classifier. evaluated whether previously published proliferation, stroma, immune-related added prognostic information Adjuvant! online tested their interaction age Cox model for...
Prospective data on the risk of recurrence among women with hormone receptor–positive early breast cancer who temporarily discontinue endocrine therapy to attempt pregnancy are lacking. Download a PDF Research Summary. We conducted single-group trial in which we evaluated temporary interruption adjuvant young previous cancer. Eligible were 42 years age or younger; had stage I, II, III disease; received for 18 30 months; and desired pregnancy. The primary end point was number events (defined...
RANKL is important in mammary gland development during pregnancy and mediates the initiation progression of progesterone-induced breast cancer. No clinical data are available on effect RANK/RANKL expression young cancer patients.We used our previously published dataset 65 pregnant 130 matched patients with full clinical, pathological, survival information. 85% had transcriptomic as well. by immunohistochemistry using H-score primary tumor adjacent normal tissue was performed. We examined...
The 1st International Consensus Conference for Breast Cancer in Young Women (BCY1) took place November 2012, Dublin, Ireland organized by the European School of Oncology (ESO). recommendations management breast cancer young women were developed and areas research priorities identified. This manuscript summarizes these international consensus recommendations, which are also endorsed Society Specialists (EUSOMA).
Purpose Previous studies have suggested an association between metformin use and improved outcome in patients with diabetes breast cancer. In the current study, we aimed to explore this human epidermal growth factor receptor 2 (HER2 ) -positive primary cancer context of a large, phase III adjuvant trial. Patients Methods The ALTTO trial randomly assigned HER2-positive receive 1 year either trastuzumab alone, lapatinib their sequence, or combination. substudy, evaluated whether at study...
In neoadjuvant trials, treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancers with dual HER2 blockade resulted in increased pathologic complete response (pCR) rates compared each targeted agent alone. Amplification and/or overexpression currently remains the only biomarker for therapeutic decisions, but it is insufficient to explain heterogeneous anti-HER2 agents.To investigate ability clinically and biologically relevant genes gene signatures (GSs) measured by...
Purpose Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA) mutations are frequently observed in primary breast cancer. We evaluated their prognostic relevance by performing a pooled analysis of individual patient data. Patients and Methods Associations between PIK3CA status clinicopathologic characteristics were tested applying Cox regression models adjusted for age, tumor size, nodes, grade, estrogen receptor (ER) status, human epidermal growth factor 2 (HER2)...
Young patients with breast cancer (BC) are often concerned about treatment-induced infertility and express maternity desire. Conception after BC does not seem to affect outcome, but information in estrogen-receptor positive (ER+) disease is definitive. From September 2012-March 2013, 212 evaluable ER+ early BC, <37 years at diagnosis, from 5 regions (Europe/US/Canada/Middle-East/Australia) answered a survey fertility concerns, desire interest study of endocrine therapy (ET) interruption...